Compound · clinical trials

Oxaliplatin clinical trials

Also listed in trial records as Eloxatin, L-Ohp, L01XA03, NSC 266046, 1-OHP, Aiheng, Dacotin, Dacplat, Eloxatine, Elplat, JM 83

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 330 trials in our China, USA, Japan, France, Spain, Italy, Canada, South Korea, Germany, Australia, Mexico, UK, Netherlands, Taiwan, Brazil, Belgium, Israel, Poland, Turkey, Czechia, Switzerland, Norway, Portugal, Austria, Sweden, Ireland, India, Denmark, Singapore and Egypt registers that name Oxaliplatin as an intervention. Synced 10 Nov 2026

330Current trials

189Recruiting now

164Lead sponsors

30Country registers

Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Synced 10 Nov 2026 · Editorial standards

At a glance

Oxaliplatin is named as an intervention in 330 current clinical trials in our China, USA, Japan, France, Spain, Italy, Canada, South Korea, Germany, Australia, Mexico, UK, Netherlands, Taiwan, Brazil, Belgium, Israel, Poland, Turkey, Czechia, Switzerland, Norway, Portugal, Austria, Sweden, Ireland, India, Denmark, Singapore and Egypt registers. 189 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Fudan University (19). The most-studied condition is Gastric Cancer. The EU clinical trials register (CTIS) separately lists 16 authorised or ongoing trials, 1 with a site in Ireland.

Where Oxaliplatin is approved

All regulators →

Of the three regulators tracked here, the first to approve Oxaliplatin was the US, on 9 Aug 2002. It is approved in 2 of the 3 regulators tracked here.

USUnited States (FDA)

9 Aug 2002

Eloxatin

NDA021492 on Drugs@FDA

First original NDA/BLA approval

EUEuropean Union (EMA)

No centralised EU authorisation (it may be authorised nationally)

First centralised authorisation

CACanada (Health Canada)

15 Jun 2007

Eloxatin

Notice of Compliance 8845

First new-drug NOC

From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.

What health systems spend on Oxaliplatin

All medicines →

ENNHS England

Not dispensed in the community in England in the last 12 months under this name

Net ingredient cost, community prescriptions

USUS Medicaid

$4.6m

54,643 prescriptions in 2025 · Oxaliplatin, oxaliplatin

-26% on 2024

Amount Medicaid reimbursed, before rebates

From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.

How Oxaliplatin works

All drug targets →

Diseases it has been tested for in clinical trials, by furthest phase

Familial gastric cancerPhase 3
NauseaPhase 3
Ampulla of vater adenocarcinomaPhase 3
Biliary tract cancerPhase 3
Carcinoma of esophagusPhase 3
Carcinoma of the ampulla of vaterPhase 3
CholangiocarcinomaPhase 3
Colon adenocarcinomaPhase 3
Colorectal adenocarcinomaPhase 3
Colorectal carcinomaPhase 3

149 diseases in all

Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL414804, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 7433, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.

NICE appraisals of Oxaliplatin

All NICE appraisals →

NICE, which decides whether the NHS in England should fund new medicines, has published 3 technology appraisals of Oxaliplatin. 2 are current, and 2 of these recommend it for at least some patients. 1 older appraisal was replaced or withdrawn.

Appraisal	NICE recommendation	Published	Status
Capecitabine and oxaliplatin in the adjuvant treatment of stage 3 (Dukes' C) colon cancer NICE TA100	Recommended	26 Apr 2006	Current
Colorectal cancer (advanced) - irinotecan, oxaliplatin and raltitrexed NICE TA93	Recommended Only in research	24 Aug 2005	Current

NICE decisions apply to the NHS in England. In Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics. Titles, categories and dates link to the guidance on nice.org.uk. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

Patient leaflets for Oxaliplatin

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

IE
Ireland: 2 products on the HPRA list
Each product record links to the HPRA, which publishes the leaflet and SmPC.
UK
United Kingdom: Search MHRA Products
Patient information leaflets and SmPCs for UK-licensed products.
US
United States: Search DailyMed
FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Reference identifiers for Oxaliplatin

ATC code: L01XA03
ChEMBL: CHEMBL414804
DrugBank: DB00526
PubChem CID: 9887054
CAS number: 61825-94-3
FDA UNII: 04ZR38536J
Wikidata: Q422327
Wikipedia: Oxaliplatin

Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.

Trials by status

Recruiting18957%
Not yet open5015%
Active, closed8927%
By invitation21%

Trials by phase

Phase 214544%
Phase 38827%
Phase 1/23511%
Phase 1278%
Phase 2/3206%
Not applicable82%
Phase 431%
Observational31%
Early Phase 110%

Clinical trials of Oxaliplatin

330 trials

Study	Phase	Status	Lead sponsor	Registers
The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials NCT05203172 · Solid Tumors	Phase 4	Recruiting	Pfizer	UK, USA, Germany, France, Spain, Italy, Netherlands, Czechia, Portugal, Turkey, Canada, Brazil, South Korea, Australia, Israel
A Prospective, Open-Label, Randomized Controlled Clinical Study Comparing Hepatic Arterial Infusion Chemotherapy (HAIC) With Capecitabine as Adjuvant Therapy After Radical Surgery for Malignant Biliary Tract Tumors NCT07790445 · ClinicalTrials.gov ↗ · Malignant Biliary Tract Tumors	Phase 4	Recruiting	Zhai Wenlong	China
Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver NCT02885753 · ClinicalTrials.gov ↗ · Colorectal Neoplasms	Phase 3	Recruiting	Federation Francophone de Cancerologie Digestive	France, Belgium
Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer NCT04215731 · ClinicalTrials.gov ↗ · Rectal Cancer	Phase 3	Recruiting	Yanhong Deng	China
A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL) NCT04365036 · ClinicalTrials.gov ↗ · NK/T Cell Lymphoma Nos	Phase 3	Recruiting	Sun Yat-sen University	China
HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT) NCT04447352 · ClinicalTrials.gov ↗ · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma	Phase 3	Recruiting	Krankenhaus Nordwest	Germany
Optimal Duration of Oxaliplatin in Adjuvant XELOX for Gastric Cancer Patients (EXODOX) NCT04787354 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 3	Recruiting	Hallym University Medical Center	South Korea
Efficacy of Hyperthermic Intraperitoneal Chemotherapy NCT04861558 · Colorectal Cancer, Peritoneal Metastases	Phase 3	Recruiting	Uppsala University	India, Sweden
Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma NCT04997837 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 3	Recruiting	Fudan University	China
Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418) NCT05008809 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 3	Recruiting	Dominik Paul Modest	Germany
Neoadjuvant FOLFOXIRI Versus CapeOX Chemotherapy for Local Advanced Rectal Cancer NCT05201430 · ClinicalTrials.gov ↗ · Rectal Cancer	Phase 3	Recruiting	Fudan University	China
PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer NCT05236972 · ClinicalTrials.gov ↗ · Colorectal Carcinoma	Phase 3	Recruiting	Sun Yat-sen University	China
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer NCT05253651 · Colorectal Neoplasms	Phase 3	Recruiting	Seagen, a wholly owned subsidiary of Pfizer	Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Austria, Norway, Portugal, Canada, Brazil, Japan, South Korea, Taiwan, Australia
Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature NCT05314998 · ClinicalTrials.gov ↗ · Pancreatic Ductal Adenocarcinoma	Phase 3	Recruiting	John Neoptolemos	Germany, Sweden
Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study NCT05342194 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma	Phase 3	Recruiting	Shanghai Junshi Bioscience Co., Ltd	China
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma NCT05677490 · ClinicalTrials.gov ↗ · Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma	Phase 3	Recruiting	Alliance for Clinical Trials in Oncology	Mexico
M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma. NCT06177041 · ClinicalTrials.gov ↗ · Locally Advanced Unresectable or Metastatic Gastric Cancer, Locally Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma	Phase 3	Recruiting	FutureGen Biopharmaceutical (Beijing) Co., Ltd	China
Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer NCT06205485 · ClinicalTrials.gov ↗ · Rectal Cancer	Phase 3	Recruiting	Canadian Cancer Trials Group	Canada, Mexico
The Sagittarius Trial NCT06490536 · ClinicalTrials.gov ↗ · Colon Cancer Stage II, Colon Cancer Stage III	Phase 3	Recruiting	IFOM ETS - The AIRC Institute of Molecular Oncology	Germany, Spain, Italy
Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma NCT06521255 · ClinicalTrials.gov ↗ · DLBCL	Phase 3	Recruiting	Beijing InnoCare Pharma Tech Co., Ltd	China
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer NCT06532006 · Gastroesophageal-junction Cancer, Monoclonal Antibody, Gastric Cancer	Phase 3	Recruiting	Shanghai Henlius Biotech	USA, China, Germany, Spain, Italy, Poland, Turkey, Brazil, Japan, South Korea, Australia
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer NCT06662786 · Colorectal Neoplasms	Phase 3	Recruiting	Janssen Research & Development, LLC	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Poland, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Israel
FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients. NCT06733038 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 3	Recruiting	Gruppo Oncologico del Nord-Ovest	Italy
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer NCT06764875 · HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma	Phase 3	Recruiting	AstraZeneca	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Austria, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia
Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma NCT06792253 · ClinicalTrials.gov ↗ · Relapsed/Refractory Diffuse Large B-Cell Lymphoma	Phase 3	Recruiting	BeBetter Med Inc	China
Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma NCT06793917 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 3	Recruiting	Fujian Cancer Hospital	China
Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer. NCT06897644 · ClinicalTrials.gov ↗ · Pancreatic Adenocarcinoma Advanced or Metastatic	Phase 3	Recruiting	Gruppo Oncologico del Nord-Ovest	Italy
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer NCT06901531 · Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer	Phase 3	Recruiting	Astellas Pharma Global Development, Inc	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Czechia, Portugal, Turkey, Brazil, Mexico, Japan, South Korea, Taiwan, Australia
AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer NCT06951503 · ClinicalTrials.gov ↗ · Colorectal Adenocarcinoma	Phase 3	Recruiting	Akeso	China
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer NCT06958328 · ClinicalTrials.gov ↗ · Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8	Phase 3	Recruiting	NRG Oncology	Canada
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) NCT06997497 · Colon Adenocarcinoma, Rectal Adenocarcinoma	Phase 3	Recruiting	Merck Sharp & Dohme LLC	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Poland, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma NCT07043400 · Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma	Phase 3	Recruiting	BeOne Medicines	UK, USA, China, France, Spain, Italy, Poland, Austria, Czechia, Turkey, Brazil, Mexico, Japan, South Korea
A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course Radiotherapy Followed by TNT in Locally Advanced Rectal Cancer NCT07113275 · ClinicalTrials.gov ↗ · Rectal Cancer, Total Neoadjuvant Therapy, Radiotherapy	Phase 3	Recruiting	Tao Zhang	China
A Phase III Study of SHR-A1811 in Combination With Chemotherapy and Adebrelimab in Previously Untreated Patients With Gastric or Gastroesophageal Junction Adenocarcinoma NCT07118527 · ClinicalTrials.gov ↗ · Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma	Phase 3	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd	China
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer NCT07228832 · Metastatic Colorectal Cancer (CRC)	Phase 3	Recruiting	Summit Therapeutics	UK, USA, China, Germany, France, Spain, Italy, Belgium, Poland, Czechia, Canada, Mexico, Japan, Egypt
Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer NCT07238283 · ClinicalTrials.gov ↗ · First-line Treatment of Metastatic Pancreatic Cancer	Phase 3	Recruiting	Jiangsu HengRui Medicine Co., Ltd	China
Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer NCT07366528 · ClinicalTrials.gov ↗ · Gastric Cancer (GC), Adjuvant Chemotherapy, Stage 3 Cancer	Phase 3	Recruiting	Ruijin Hospital	China
Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma. NCT07385703 · ClinicalTrials.gov ↗ · Adenocarcinoma	Phase 3	Recruiting	Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd	China, Japan
Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer NCT07389265 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer (mCRC)	Phase 3	Recruiting	University of Campania Luigi Vanvitelli	Spain, Italy
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer NCT07409272 · Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma	Phase 3	Recruiting	Astellas Pharma Global Development, Inc	UK, USA, China, Germany, France, Spain, Poland, Brazil, Japan, South Korea, Taiwan
A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL NCT07409428 · ClinicalTrials.gov ↗ · Relapsed/Refractory Diffuse Large B-Cell Lymphoma	Phase 3	Recruiting	Hutchmed	China
Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer NCT07412613 · ClinicalTrials.gov ↗ · Resectable Colon Cancer, MSI-H/dMMR Colorectal Cancer	Phase 3	Recruiting	Akeso	China
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2 NCT07431281 · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer	Phase 3	Recruiting	AstraZeneca	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Austria, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia
Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer NCT07472868 · ClinicalTrials.gov ↗ · Locally Advanced Rectal Carcinoma	Phase 3	Recruiting	J. W. A. Burger	Netherlands
A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma NCT07570823 · ClinicalTrials.gov ↗ · DLBCL - Diffuse Large B Cell Lymphoma	Phase 3	Recruiting	Sinocelltech Ltd	China
A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01) NCT07582315 · ClinicalTrials.gov ↗ · Biliary Tract Cancer	Phase 3	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd	China
A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure NCT07606599 · ClinicalTrials.gov ↗ · Biliary Tract Cancer	Phase 3	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd	China
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 ) NCT07621718 · Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC	Phase 3	Recruiting	Revolution Medicines, Inc	UK, USA, Italy, Netherlands, Austria
A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer NCT07673887 · Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma	Phase 3	Recruiting	Astellas Pharma Global Development, Inc	USA, China, Japan
QLS31905 in Combination With CAPOX Versus Sintilimab in Combination With CAPOX as First-line Treatment in Patients With GC/GEJ NCT07716449 · ClinicalTrials.gov ↗ · Gastric or Gastroesophageal Junction Adenocarcinoma	Phase 3	Recruiting	Qilu Pharmaceutical Co., Ltd	China
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2) NCT07775287 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 3	Recruiting	Genmab	USA
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) NCT05139017 · DLBCL, Diffuse Large B-Cell Lymphoma	Phase 2/3	Recruiting	Merck Sharp & Dohme LLC	UK, USA, China, France, Italy, Denmark, Poland, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Australia, Israel
Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer NCT05699655 · ClinicalTrials.gov ↗ · Immunotherapy Gastrict Cancer	Phase 2/3	Recruiting	Fujian Cancer Hospital	China
Radiation Therapy in Unresectable Gall Bladder Cancer NCT06214572 · Gall Bladder Cancer	Phase 2/3	Recruiting	Tata Memorial Centre	India
Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations NCT06279130 · ClinicalTrials.gov ↗ · Resectable MMR-deficient Solid Tumors, Resectable MMR-proficient Solid Tumors	Phase 2/3	Recruiting	The Netherlands Cancer Institute	Netherlands
Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients NCT06280495 · ClinicalTrials.gov ↗ · Colorectal Cancer, Liver Metastases	Phase 2/3	Recruiting	Sun Yat-sen University	China
Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer NCT06441565 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 2/3	Recruiting	Sun Yat-sen University	China
Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma NCT06841679 · Gastric or Gastroesophageal Junction Adenocarcinoma	Phase 2/3	Recruiting	Beijing Biostar Pharmaceuticals Co., Ltd	USA, China
A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment. NCT07490262 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC)	Phase 2/3	Recruiting	Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD	China
A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma NCT07490301 · Metastatic Pancreatic Ductal Adenocarcinoma, PDAC	Phase 2/3	Recruiting	AbbVie	UK, USA, China, Portugal, Japan, South Korea, Taiwan, Australia, Israel
Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Resectable Gastric/Gastroesophageal Junction Adenocarcinoma NCT07643623 · ClinicalTrials.gov ↗ · Resectable Gastric/Gastroesophageal Junction Adenocarcinoma	Phase 2/3	Recruiting	Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD	China
Adjuvant Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in Resected High Risk Colon Cancer Patients NCT03280511 · ClinicalTrials.gov ↗ · Peritoneum Cancer, Peritoneal Carcinomatosis, Peritoneal Metastases	Phase 2	Recruiting	Michael Bau Mortensen	Denmark
Conversion From Unresectable To Resectable Metastatic Colorectal Cancer. NCT03401294 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer	Phase 2	Recruiting	University of Saskatchewan	Canada
Pan Tumor Rollover Study NCT03899155 · Cancer	Phase 2	Recruiting	Bristol-Myers Squibb	Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Switzerland, Austria, Czechia, Norway, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
ONO-4538 Phase II Rollover Study (ONO-4538-98) NCT04566380 · ClinicalTrials.gov ↗ · Pan-tumor	Phase 2	Recruiting	Ono Pharmaceutical Co., Ltd	Japan, South Korea, Taiwan
Docetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel Obstruction NCT04840264 · ClinicalTrials.gov ↗ · Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Peritoneal Carcinomatosis	Phase 2	Recruiting	Sixth Affiliated Hospital, Sun Yat-sen University	China
Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery NCT04891289 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma	Phase 2	Recruiting	Memorial Sloan Kettering Cancer Center	Netherlands
S-1 and Oxaliplatin (SOX) Plus Sintilimab in the Locally Advanced Esophagogastric Junction Adenocarcinoma NCT04989985 · ClinicalTrials.gov ↗ · Locally Advanced Gastroesophageal Junction Adenocarcinoma, Chemotherapy Effect	Phase 2	Recruiting	Sixth Affiliated Hospital, Sun Yat-sen University	China
Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus) NCT05177133 · ClinicalTrials.gov ↗ · Gastric Adenocarcinoma, Esophageal Adenocarcinoma	Phase 2	Recruiting	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	Netherlands
A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC) NCT05472259 · ClinicalTrials.gov ↗ · Metastatic Pancreatic Ductal Adenocarcinoma	Phase 2	Recruiting	Belgian Group of Digestive Oncology	Belgium
The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy) NCT05536102 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 2	Recruiting	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	China
The Combination of Immunotherapy and Neoadjuvant Short-course Radiotherapy in Early Rectal Cancer NCT05555888 · ClinicalTrials.gov ↗ · Early Low Rectal Cancer	Phase 2	Recruiting	Fudan University	China
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial NCT05564377 · ClinicalTrials.gov ↗ · Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8	Phase 2	Recruiting	National Cancer Institute (NCI)	Mexico, Israel, Egypt
Neoadjuvant Treatment With mFOLFOXIRI Plus Cadonilimab (AK104) Versus mFOLFOX6 in Locally Advanced Colorectal Cancer NCT05571644 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 2	Recruiting	Sun Yat-sen University	China
Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma NCT05687357 · ClinicalTrials.gov ↗ · Gastric Cancer, Gastroesophageal-junction Cancer	Phase 2	Recruiting	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	China
FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients NCT05727163 · ClinicalTrials.gov ↗ · Colorectal Cancer Metastatic	Phase 2	Recruiting	Sun Yat-sen University	China
Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma NCT05729646 · ClinicalTrials.gov ↗ · Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, Mismatch Repair Deficiency	Phase 2	Recruiting	Yu jiren	China
Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer NCT05731726 · ClinicalTrials.gov ↗ · pMMR, MSS, MSI-L	Phase 2	Recruiting	Zhejiang University	China
A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer NCT05859750 · ClinicalTrials.gov ↗ · Pancreatic Cancer	Phase 2	Recruiting	Akeso	China
Perioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcinoma (FOCUS-05) NCT05872685 · ClinicalTrials.gov ↗ · Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, Proficient Mismatch Repair	Phase 2	Recruiting	Yu jiren	China
Induction Chemotherapy Combined With Neoadjuvant Immunotherapy for MSS Colon Cancer NCT05914389 · ClinicalTrials.gov ↗ · Colon Neoplasm	Phase 2	Recruiting	Second Affiliated Hospital, Zhejiang University, School of Medicine	China
Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma NCT05960955 · ClinicalTrials.gov ↗ · Resectable Gastric or Gastroesophageal Junction Adenocarcinoma	Phase 2	Recruiting	Akeso	China
Nodes-sparing Short-course Radiation Combined With CAPOX and Tislelizumab for MSS Middle and Low Rectal Cancer NCT05972655 · ClinicalTrials.gov ↗ · Low Rectal Cancer	Phase 2	Recruiting	Sir Run Run Shaw Hospital	China
Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma. NCT06155383 · ClinicalTrials.gov ↗ · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma	Phase 2	Recruiting	RemeGen Co., Ltd	China
Camrelizumab Combined With Chemotherapy and Radiotherapy Perioperative Treatment of Esophageal Gastric Junction Adenocarcinoma NCT06163729 · ClinicalTrials.gov ↗ · Gastroesophageal Junction Adenocarcinoma (Siewert II-III)	Phase 2	Recruiting	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
Node-sparing Radiotherapy Combined With Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer NCT06204094 · ClinicalTrials.gov ↗ · Locally Advanced Rectal Cancer	Phase 2	Recruiting	Jinhua Central Hospital	China
Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors NCT06208462 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma	Phase 2	Recruiting	The First Affiliated Hospital with Nanjing Medical University	China
Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer NCT06245356 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer, Metastatic Gastroesophageal Adenocarcinoma, DPD Deficiency	Phase 2	Recruiting	UNICANCER	France
First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer NCT06253611 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 2	Recruiting	GERCOR - Multidisciplinary Oncology Cooperative Group	France
The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra Low Rectal Adenocarcinoma NCT06266832 · ClinicalTrials.gov ↗ · Rectal Adenocarcinoma	Phase 2	Recruiting	Sir Run Run Shaw Hospital	China
CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for MSS Locally Advanced Rectal Cancer NCT06281405 · ClinicalTrials.gov ↗ · Locally Advanced Rectal Cancer, Neoadjuvant Therapy	Phase 2	Recruiting	Fudan University	China
Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer NCT06282445 · ClinicalTrials.gov ↗ · Colorectal Cancer Metastatic	Phase 2	Recruiting	The Fourth Affiliated Hospital of Zhejiang University School of Medicine	China
Concurrent Chemoradiotherapy Combined With Sintilimab as Neoadjuvant Therapy for GC Patients With PALM NCT06341595 · ClinicalTrials.gov ↗ · Gastric Cancer, Gastric Cancer Metastatic to Regional Lymph Nodes	Phase 2	Recruiting	The First Affiliated Hospital with Nanjing Medical University	China
Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer NCT06368141 · ClinicalTrials.gov ↗ · Colon Cancer	Phase 2	Recruiting	Ruijin Hospital	China
NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC NCT06405490 · ClinicalTrials.gov ↗ · Nanoliposomal Irinotecan, Cadonilimab, Oxaliplatin	Phase 2	Recruiting	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
Neoadjuvant Immunotherapy Plus Chemotherapy in Borrmann Type 4 and Large Type 3 Gastric Cancer NCT06451211 · ClinicalTrials.gov ↗ · Stomach Neoplasms, Gastric Cancer, Linitis Plastica of Stomach	Phase 2	Recruiting	Sun Yat-sen University	China
Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer (TORCH-LE) NCT06455124 · ClinicalTrials.gov ↗ · Rectal Cancer	Phase 2	Recruiting	Fudan University	China
Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma NCT06461910 · ClinicalTrials.gov ↗ · Gastric Cancer, Esophagogastric Junction Adenocarcinoma	Phase 2	Recruiting	Zekuan Xu	China
Short-course Radiotherapy Combined With CAPOX and PD-1 Antibody Versus Long-course Chemoradiotherapy Combined With CAPOX for Early Low-lying Rectal Cancer NCT06462053 · ClinicalTrials.gov ↗ · Early Low Rectal Cancer	Phase 2	Recruiting	Fudan University	China
Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL NCT06489808 · ClinicalTrials.gov ↗ · Relapsed/Refractory Large B-Cell Lymphoma	Phase 2	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients NCT06493760 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer	Phase 2	Recruiting	Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd	China
Adebelimab Combined With Irinotecan Liposomal Injection, Oxaliplatin, Fluorouracil and Calcium Folinate Are Used in the First-line Treatment of Pancreatic Cancer Liver Metastasis Efficacy and Safety NCT06531278 · ClinicalTrials.gov ↗ · Pancreatic Cancer Metastatic to Liver	Phase 2	Recruiting	Jiang Long	China
Sintilimab With P-GEMOX Versus the P-GEMOX in the Teatment of Advanced-stage Extranodal Natural Killer/T Cell Lymphoma NCT06583083 · ClinicalTrials.gov ↗ · Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type	Phase 2	Recruiting	Sun Yat-sen University	China
Efficacy and Safety of Penpulimab Combined With Anlotinib and Chemotherapy NCT06586242 · ClinicalTrials.gov ↗ · Esophageal Cancer	Phase 2	Recruiting	Xijing Hospital	China
Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer NCT06630130 · ClinicalTrials.gov ↗ · Stomach Neoplasms	Phase 2	Recruiting	Jeeyun Lee	South Korea
First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2) NCT06730373 · ClinicalTrials.gov ↗ · HER2-positive Gastric Cancer, Metastatic Gastric Cancer, Unresectable Gastric Carcinoma	Phase 2	Recruiting	Qilu Hospital of Shandong University	China
SCRT(Short Course Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver Metastases NCT06787183 · ClinicalTrials.gov ↗ · Locally Advanced Rectal Cancer With Liver Metastases	Phase 2	Recruiting	Fujian Cancer Hospital	China
PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM NCT06788171 · ClinicalTrials.gov ↗ · Colorectal Cancer Liver Metastasis	Phase 2	Recruiting	Fujian Cancer Hospital	China
Short-course Radiotherapy Followed by AK112 and CAPOX as Neoadjuvant Therapy for Locally Advanced Rectal Cancer NCT06802666 · ClinicalTrials.gov ↗ · Locally Advanced Rectal Cancer, Neoadjuvant Therapy	Phase 2	Recruiting	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	China
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL NCT06806033 · ClinicalTrials.gov ↗ · Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma	Phase 2	Recruiting	Hoffmann-La Roche	USA, Germany, France, Italy, Canada, South Korea, Australia
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer NCT06820463 · Metastatic Colorectal Cancer	Phase 2	Recruiting	AbbVie	UK, USA, France, Spain, Italy, Austria, Czechia, Canada, Brazil, Japan, Taiwan, Australia, Israel
MR-guided Adaptive Radiotherapy Combined With PD-1 Antibody and CAPOX for Locally Advanced Rectal Cancer NCT06840665 · ClinicalTrials.gov ↗ · Locally Advanced Rectal Cancer	Phase 2	Recruiting	Fudan University	China
Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma NCT06846346 · ClinicalTrials.gov ↗ · Metastatic Esophageal Adenocarcinoma, Advanced Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma	Phase 2	Recruiting	UNICANCER	France
Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma NCT06854445 · ClinicalTrials.gov ↗ · Diffuse Large Cell B-lymphoma	Phase 2	Recruiting	Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd	China
CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Locally Recurrent Colorectal Cancer NCT06881537 · ClinicalTrials.gov ↗ · Locally Recurrent Colorectal Cancer	Phase 2	Recruiting	Shanghai Changzheng Hospital	China
A Phase 2 Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in Combination With Chemotherapy in Patients With Colorectal Cancer NCT06885385 · ClinicalTrials.gov ↗ · Advanced Colorectal Cancer	Phase 2	Recruiting	Shanghai Junshi Bioscience Co., Ltd	China
Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer NCT06928584 · ClinicalTrials.gov ↗ · Locally Recurrent Rectal Cancer	Phase 2	Recruiting	Fudan University	China
A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer NCT06948448 · Colorectal Cancer	Phase 2	Recruiting	Ono Pharmaceutical Co., Ltd	USA, France, Spain, Italy, Canada, Japan
An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma NCT07018570 · ClinicalTrials.gov ↗ · Gastroesophageal Junction (GEJ) Adenocarcinoma	Phase 2	Recruiting	National Cancer Center Hospital East	Japan
Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer NCT07025174 · ClinicalTrials.gov ↗ · Bile Duct Carcinoma, Gall Bladder Cancer, Biliary Tract Cancer	Phase 2	Recruiting	First Affiliated Hospital of Zhejiang University	China
Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma NCT07030140 · ClinicalTrials.gov ↗ · Cholangiocarcinoma, Hilar Cholangiocarcinoma, Bile Duct Cancer	Phase 2	Recruiting	Jinbo Yue	China
Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC) NCT07150949 · ClinicalTrials.gov ↗ · Locally Advanced Rectal Cancer, Neoadjuvant Therapy	Phase 2	Recruiting	Fudan University	China
Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05) NCT07165847 · ClinicalTrials.gov ↗ · Immunotherapy, Gastric Cancer (GC), Radiotherapy	Phase 2	Recruiting	Daping Hospital and the Research Institute of Surgery of the Third Military Medical University	China
Clinical Trial of Neoadjuvant mFOLFOX Plus Alvenor for LARC Patients With High YWHAB Expression NCT07176182 · ClinicalTrials.gov ↗ · Rectal Cancer Patients, Rectal Cancer Stage II, Rectal Cancer Stage III	Phase 2	Recruiting	Sixth Affiliated Hospital, Sun Yat-sen University	China
Conversion Therapy With RC48, Sintilimab, and SOX for HER2 1+/2+ Unresectable Gastric Cancer NCT07194005 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 2	Recruiting	Fudan University	China
A Pilot Study Evaluating β-hydroxybutyrate Supplementation Concomitant to Short-Course Radiotherapy Followed by Immunotherapy Combined With CAPEOX Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer NCT07239466 · ClinicalTrials.gov ↗ · Rectal Cancer, Radiotherapy, Immunotherapy	Phase 2	Recruiting	Tao Zhang	China
AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas NCT07290985 · ClinicalTrials.gov ↗ · Gastroesophageal Adenocarcinoma	Phase 2	Recruiting	American Association for Cancer Research	Canada
SHR-1701 Combined With Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis NCT07384234 · ClinicalTrials.gov ↗ · Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma	Phase 2	Recruiting	Ruijin Hospital	China
A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04] NCT07390383 · ClinicalTrials.gov ↗ · Advanced Solid Tumour	Phase 2	Recruiting	Nanjing Leads Biolabs Co.,Ltd	China
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies NCT07415031 · Solid Tumors	Phase 2	Recruiting	Mirati Therapeutics Inc	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Portugal, Canada, Brazil, Japan, South Korea, Singapore, Australia, Israel
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2) NCT07432295 · Solid Tumor, Advanced Cancer, Metastatic Cancer	Phase 2	Recruiting	I-Mab Biopharma US Limited	USA, China, Japan, Egypt
Low Dose Epcoritamab Plus GemOx in R/R DLBCL NCT07451652 · ClinicalTrials.gov ↗ · Relapsed/Refractory Diffuse Large B Cell Lymphoma	Phase 2	Recruiting	Hospital Universitario Dr. Jose E. Gonzalez	Mexico
Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer NCT07469306 · ClinicalTrials.gov ↗ · Locally Advanced Rectal Cancer	Phase 2	Recruiting	Fujian Cancer Hospital	China
A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer NCT07474727 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 2	Recruiting	Multitude Therapeutics Inc	China
JS212 Combination Therapies in Metastatic Colorectal Cancer NCT07503756 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer	Phase 2	Recruiting	Shanghai Junshi Bioscience Co., Ltd	China
A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States NCT07554521 · Advanced Unresectable Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Advanced Gastroesophageal Adenocarcinoma	Phase 2	Recruiting	BeOne Medicines	USA
HIPEC Priming Followed by Serplulimab Plus SOX/XELOX in Locally Advanced Gastric Cancer NCT07621484 · ClinicalTrials.gov ↗ · Locally Advanced Gastric Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma	Phase 2	Recruiting	Shanghai Changzheng Hospital	China
Perioperative HLX10 (Serplulimab) With S-1+Oxaliplatin (SOX) in Locally Advanced and PD-L1-Positive Gastric or Esophagogastric Junction Adenocarcinoma NCT07699939 · ClinicalTrials.gov ↗ · Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma	Phase 2	Recruiting	National Cancer Center, Japan	Japan, South Korea
A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC NCT07733180 · ClinicalTrials.gov ↗ · Advanced Esophageal Squamous Cell Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma	Phase 2	Recruiting	BeOne Medicines	Japan
A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002) NCT07793942 · ClinicalTrials.gov ↗ · Malignant Neoplam, Advanced Solid Tumors	Phase 2	Recruiting	Merck Sharp & Dohme LLC	USA, Switzerland, Canada
Sintilimab Plus NALIRIFOX or Gemcitabine-Cisplatin as First-Line Treatment for Metastatic Biliary Tract Cancer NCT07831993 · ClinicalTrials.gov ↗ · Biliary Tract Cancer	Phase 2	Recruiting	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	China
Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab NCT05319639 · ClinicalTrials.gov ↗ · Gastric Cancer Stage IV	Phase 1/2	Recruiting	Fujian Cancer Hospital	China
A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer NCT05379595 · Advanced or Metastatic Colorectal Cancer	Phase 1/2	Recruiting	Janssen Research & Development, LLC	USA, China, Germany, Spain, Italy, Belgium, Canada, South Korea, Taiwan
FOG-001 in Locally Advanced or Metastatic Solid Tumors NCT05919264 · ClinicalTrials.gov ↗ · Cancer, Colorectal Cancer, Solid Tumor	Phase 1/2	Recruiting	Parabilis Medicines, Inc	USA, Australia
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation NCT06385925 · Malignant Neoplasm	Phase 1/2	Recruiting	Tyligand Pharmaceuticals (Suzhou) Limited	USA, China
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) NCT06469944 · ClinicalTrials.gov ↗ · Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	USA, China, Germany, France, Italy, Switzerland, Norway, Brazil, South Korea, Taiwan
A Phase Ib/II Trial of Neoadjuvant Zolbetuximab Plus Docetaxel, Oxaliplatin and S-1 Chemotherapy in Patients With Locally Advanced Gastric Cancer NCT06732856 · ClinicalTrials.gov ↗ · Stomach Neoplasm, Gastric (Stomach) Cancer	Phase 1/2	Recruiting	Asan Medical Center	South Korea
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors NCT06741644 · Advanced Solid Tumors	Phase 1/2	Recruiting	CStone Pharmaceuticals	USA, China, Australia
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) NCT06780111 · Esophageal Squamous Cell Carcinoma	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	USA, China, Germany, France, Italy, Switzerland, Czechia, Norway, Turkey, Brazil, Japan, South Korea, Taiwan, Singapore
Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LV NCT06782685 · ClinicalTrials.gov ↗ · Advanced Pancreatic Cancer (Part 1)	Phase 1/2	Recruiting	Dai, Guanghai	China
Clinical Studies for the Treatment of Advanced Solid Tumors NCT06825494 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Phase 1/2	Recruiting	Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd	China
A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer NCT06840002 · ClinicalTrials.gov ↗ · Ovarian Cancer	Phase 1/2	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd	China
IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer NCT07025889 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 1/2	Recruiting	Ruijin Hospital	China
Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer NCT07056777 · ClinicalTrials.gov ↗ · Gastrointestinal Cancer	Phase 1/2	Recruiting	Zhejiang Doer Biologics Co., Ltd	China
A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma NCT07124936 · ClinicalTrials.gov ↗ · Diffuse Large B Cell Lymphoma (DLBCL)	Phase 1/2	Recruiting	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd	China
A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors NCT07256782 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Phase 1/2	Recruiting	Qilu Pharmaceutical Co., Ltd	China
A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients. NCT07283367 · ClinicalTrials.gov ↗ · CRC	Phase 1/2	Recruiting	Hansoh BioMedical R&D Company	China
CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors NCT07335497 · Locally Advanced / Metastatic Solid Tumors	Phase 1/2	Recruiting	Crescent Biopharma, Inc	Ireland, UK, USA, France, Spain, Italy, South Korea, Australia
Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRC NCT07365592 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 1/2	Recruiting	Second Affiliated Hospital, Zhejiang University, School of Medicine	China
Low Rectal Cancer Treated With Total Neoadjuvant Therapy Plus Concurrent Tislelizumab Immunotherapy NCT07561060 · ClinicalTrials.gov ↗ · Rectal Cancer	Phase 1/2	Recruiting	Fudan University	China
A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer. NCT07653685 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 1/2	Recruiting	Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd	China
A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation NCT07678593 · Advanced Solid Tumors Cancer, Pancreatic Ductal Adenocarcinoma, RAS Mutation	Phase 1/2	Recruiting	Genfleet Therapeutics (Shanghai) Inc	China, Australia
IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer NCT07692750 · Advanced Pancreatic Cancer	Phase 1/2	Recruiting	Zhejiang Cancer Hospital	China
A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors NCT07730021 · Locally Advanced or Metastatic Solid Tumors	Phase 1/2	Recruiting	Astellas Pharma Global Development, Inc	USA, Japan
A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal Carcinoma NCT07791758 · ClinicalTrials.gov ↗ · Metastatic Colorectal Carcinoma	Phase 1/2	Recruiting	Nanjing Leads Biolabs Co.,Ltd	China
A Study of HDM2017 Combination Therapy in Advanced Colorectal Cancer NCT07805551 · ClinicalTrials.gov ↗ · CRC, Colorectal Cancer	Phase 1/2	Recruiting	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd	China
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001) NCT05067283 · Advanced Solid Tumors	Phase 1	Recruiting	Merck Sharp & Dohme LLC	USA, China, Spain, Italy, Denmark, Poland, Switzerland, Turkey, Canada, Japan, South Korea, Taiwan, Australia, Israel
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer NCT05365581 · Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma	Phase 1	Recruiting	Astellas Pharma Global Development, Inc	USA, China, France, Spain, Italy, Japan, South Korea
A Study of ASP3082 in Adults With Advanced Solid Tumors NCT05382559 · Solid Tumor	Phase 1	Recruiting	Astellas Pharma Inc	USA, China, France, Spain, Japan, South Korea, Israel
In Vivo Lung Perfusion (IVLP) for Colorectal Cancer Metastatic to Lung NCT05611034 · ClinicalTrials.gov ↗ · Lung Metastases, Colorectal Cancer Metastatic, Colorectal Cancer	Phase 1	Recruiting	University Health Network, Toronto	Canada
A Study of ASP1002 in Adults for Treatment of Solid Tumors NCT05719558 · Advanced Solid Tumors	Phase 1	Recruiting	Astellas Pharma Global Development, Inc	USA
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors NCT06131840 · Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms	Phase 1	Recruiting	Seagen, a wholly owned subsidiary of Pfizer	UK, USA, China, France, Spain, Netherlands, Sweden, Canada, Japan, Israel
ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer NCT06825624 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer (CRC)	Phase 1	Recruiting	Hansoh BioMedical R&D Company	China
A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies NCT06839105 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Melanoma and Other Solid Tumor	Phase 1	Recruiting	Shanghai Junshi Bioscience Co., Ltd	China
The Role of Coenzyme Q10 in the Prophylaxis of Oxaliplatin Induced Peripheral Neuropathy in Patients With Colorectal Cancer NCT06856447 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 1	Recruiting	toqa saad mohammed mohammed	Egypt
A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer NCT07024615 · Pancreatic Ductal Adenocarcinoma	Phase 1	Recruiting	Astellas Pharma Global Development, Inc	USA
Paclitaxel Cationic Liposome (Hepatic Arterial Infusion) in Combination With Systemic Therapy as First-Line Treatment in Colorectal Liver Metastases NCT07117435 · ClinicalTrials.gov ↗ · Colorectal Liver Metastases, First-line Treatment	Phase 1	Recruiting	CSPC ZhongQi Pharmaceutical Technology Co., Ltd	China
A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies NCT07308132 · ClinicalTrials.gov ↗ · Lymphoma, Non-Hodgkin	Phase 1	Recruiting	Janssen Research & Development, LLC	France, Spain, Belgium, Turkey, Australia
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors NCT07318805 · Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Colorectal Cancer	Phase 1	Recruiting	Pfizer	USA, France, Spain
A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combinations in Advanced Solid Tumors NCT07477743 · ClinicalTrials.gov ↗ · Advanced Solid Tumor Cancer	Phase 1	Recruiting	HC Biopharma Inc	China
HEC-921 Injection as Monotherapy and in Combination With Antineoplastic Therapies in Patients With Advanced Malignant Solid Tumors NCT07824934 · ClinicalTrials.gov ↗ · Advanced Malignant Solid Tumors	Phase 1	Recruiting	Sunshine Lake Pharma Co., Ltd	China
The ADAPTA Study: ADjuvant chemotherAPy After Curative Intent resecTion of Ampullary Cancer. NCT06068023 · ClinicalTrials.gov ↗ · Ampullary Adenocarcinoma	Observational	Recruiting	Fondazione Poliambulanza Istituto Ospedaliero	Italy
Chemotherapy Combined with Immunotherapy and Targeted Therapy in Cholangiocarcinoma NCT06718257 · ClinicalTrials.gov ↗ · Cholangiocarcinoma	Observational	Recruiting	Second Affiliated Hospital, Zhejiang University, School of Medicine	China
Chemoradiation and Consolidation Chemotherapy With or Without Oxaliplatin for Distal Rectal Cancer and Watch and Wait NCT05000697 · ClinicalTrials.gov ↗ · Rectal Cancer, Consolidation	Not applicable	Recruiting	Hospital Alemão Oswaldo Cruz	Brazil
Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic Cancer NCT06361316 · ClinicalTrials.gov ↗ · Pancreatic Cancer, Adjuvant Therapy	Not applicable	Recruiting	Kuirong Jiang	China
NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus AG Combined With PD-1 Sequential Radiotherapy as First-line Treatment of Locally Advanced Pancreatic Cancer NCT06494514 · ClinicalTrials.gov ↗ · Locally Advanced Pancreatic Cancer	Not applicable	Recruiting	Du Juan	China
Preoperative Chemoradiotherapy Combined With Consolidation or Induction NALIRIFOX in Rectal Cancer. NCT06894797 · ClinicalTrials.gov ↗ · Locally Advanced Rectal Cancer	Not applicable	Recruiting	Peking University Cancer Hospital & Institute	China
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays NCT07283939 · ClinicalTrials.gov ↗ · Ampulla of Vater Carcinoma, Appendix Carcinoma, Carcinoma of Unknown Primary With Gastrointestinal Profile	Not applicable	Recruiting	Alliance for Clinical Trials in Oncology	Mexico
SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC NCT07474103 · Rectal Cancer, Adenocarcinoma	Not applicable	Recruiting	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	China
Effect and Safety of Huaier Granule Versus SOX Regimen in Gastric Cancer Patients NCT05498766 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 4	Not yet open	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	China
CAPEOX vs Observation in Colorectal Cancer Patients With Positive MRD NCT05699746 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 3	Not yet open	Zhejiang University	China
HR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cancer NCT06217042 · ClinicalTrials.gov ↗ · Pancreatic Cancer	Phase 3	Not yet open	Fudan University	China
Pre-Operative Treatment in REseCTable COlon CanceR NCT06899477 · ClinicalTrials.gov ↗ · Colo-rectal Cancer, Colon Cancer, Colon Carcinoma	Phase 3	Not yet open	Dominik Paul Modest	Germany
A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma NCT06944496 · ClinicalTrials.gov ↗ · Gastric Carcinoma	Phase 3	Not yet open	RemeGen Co., Ltd	China
Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer NCT07132008 · ClinicalTrials.gov ↗ · Colonic Neoplasms, Neoadjuvant Therapy, Immune Checkpoint Inhibitors	Phase 3	Not yet open	First Affiliated Hospital of Guangxi Medical University	China
SCRT Based iTNT vs. LCRT Based TNT for MSS Locally Advanced Rectal Cancer NCT07551479 · ClinicalTrials.gov ↗ · Locally Advanced Rectal Cancer (LARC), MSS (Microsatellite Stable)	Phase 3	Not yet open	Fudan University	China
Chemotherapy Combined With or Without Short-Course Radiotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for High-Risk Locally Advanced Colon Cancer With pMMR/MSS NCT07877597 · ClinicalTrials.gov ↗ · Locally Advanced Colon Cancer, pMMR	Phase 3	Not yet open	Fudan University	China
Hepatic Arterial Infusion Chemotherapy Versus Capecitabine as Adjuvant Therapy for Resected Biliary Tract Cancer NCT07916844 · ClinicalTrials.gov ↗ · Biliary Tract Cancer, Cholangiocarcinoma, Gallbladder Cancer	Phase 3	Not yet open	Zhai Wenlong	China
Sintilimab Combined With LCCRT Followed by Capeox Chemotherapy in pMMR/MSS/MSI-L Locally Advanced Rectal Cancer NCT07917468 · ClinicalTrials.gov ↗ · Locally Advanced Rectal Cancer	Phase 3	Not yet open	Innovent Biologics (Suzhou) Co. Ltd	China
A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma NCT05976568 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 2/3	Not yet open	Qilu Pharmaceutical Co., Ltd	China
Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment NCT06662877 · ClinicalTrials.gov ↗ · Biliary Tract Cancer, Second Line Treatment, Chemotherapy	Phase 2/3	Not yet open	Sun Yat-sen University	China
A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma NCT07392866 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC)	Phase 2/3	Not yet open	Nanjing Sanhome Pharmaceutical, Co., Ltd	China
Testing Mitazalimab in Combination With Standard Chemotherapy in Immunotherapy Resistant Advanced Biliary Tract Cancers NCT07437287 · ClinicalTrials.gov ↗ · Biliary Tract Cancer (BTC)	Phase 2/3	Not yet open	UNICANCER	France
An Adaptive-design Prospective Cohort Study of Watch and Wait Strategy in Patients With Locally Advanced Rectal Cancer NCT04443543 · ClinicalTrials.gov ↗ · Rectal Cancer	Phase 2	Not yet open	Fudan University	China
Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes NCT05524974 · ClinicalTrials.gov ↗ · Locally Advanced Gastric Cancer	Phase 2	Not yet open	Fujian Medical University	China
Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma NCT05970627 · ClinicalTrials.gov ↗ · Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, Epstein-Barr Virus-Associated Gastric Carcinoma	Phase 2	Not yet open	Yu jiren	China
Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer NCT06166589 · ClinicalTrials.gov ↗ · Previously AG Chemotherapy Treated Pancreatic Cancer	Phase 2	Not yet open	Shanghai Zhongshan Hospital	China
Neoadjuvant Cadonilimab Plus Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial NCT06310473 · ClinicalTrials.gov ↗ · Gastric Cancer, Esophagogastric Junction Cancer	Phase 2	Not yet open	Nanfang Hospital, Southern Medical University	China
Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors NCT06446388 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Phase 2	Not yet open	Qilu Pharmaceutical Co., Ltd	China
Mecapegfilgrastim Combined With Adebrelimab and Chemotherapy as Neoadjuvant Therapy in Resectable GC/GEJC NCT06684158 · ClinicalTrials.gov ↗ · GC/GEJC	Phase 2	Not yet open	The First Affiliated Hospital with Nanjing Medical University	China
Preoperative Chemoradiotherapy and Toripalimab in Locally Recurrent Rectal Cancer NCT06751394 · Recurrent Rectal Cancer	Phase 2	Not yet open	Sixth Affiliated Hospital, Sun Yat-sen University	China
Short-Course Radiotherapy Combined with Intracavitary Brachytherapy Followed by Pucotenlimab, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil (TAS-102) for Total Neoadjuvant Therapy of Microsatellite Stable (MSS) Locally Advanced Low Rectal Cancer NCT06872606 · ClinicalTrials.gov ↗ · Rectal Adenocarcinoma	Phase 2	Not yet open	Sir Run Run Shaw Hospital	China
Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer NCT07018063 · ClinicalTrials.gov ↗ · Gastric (Cardia, Body) Cancer, Stomach Adenocarcinoma, Locally Advanced	Phase 2	Not yet open	zhoujing	China
PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment NCT07028424 · ClinicalTrials.gov ↗ · PDAC - Pancreatic Ductal Adenocarcinoma	Phase 2	Not yet open	GERCOR - Multidisciplinary Oncology Cooperative Group	France
Efficacy and Safety of AK112 Combined Chemotherapy as Neoadjuvant Treatment for Signet Ring Cell-containing G/GEJ Adenocarcinoma NCT07091227 · ClinicalTrials.gov ↗ · Gastric or Gastroesophageal Junction Adenocarcinoma	Phase 2	Not yet open	Peking Union Medical College Hospital	China
Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer NCT07150403 · ClinicalTrials.gov ↗ · Metastatic Colorectal Carcinoma (mCRC)	Phase 2	Not yet open	Federation Francophone de Cancerologie Digestive	France
A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation NCT07229846 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 2	Not yet open	Yanqiao Zhang	China
Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinoma NCT07374250 · ClinicalTrials.gov ↗ · Gastric Cancer, RCT	Phase 2	Not yet open	Sichuan University	China
Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma NCT07554482 · ClinicalTrials.gov ↗ · Extranodal NK/T-cell Lymphoma	Phase 2	Not yet open	Beijing Tongren Hospital	China
A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma NCT07599423 · ClinicalTrials.gov ↗ · Diffuse Large B Cell Lymphoma (DLBCL)	Phase 2	Not yet open	The First Affiliated Hospital of Soochow University	China
FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II) NCT07621497 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer (CRC)	Phase 2	Not yet open	Sun Yat-sen University	China
RESTAGE (REpurposing STAtins to Improve Outcomes in GastroEsophageal Cancer) Trial NCT07625930 · ClinicalTrials.gov ↗ · Gastroesophageal Adenocarcinoma	Phase 2	Not yet open	McGill University Health Centre/Research Institute of the McGill University Health Centre	Canada
Mannatide Combined With CAPOX and Tislelizumab for Advanced Gastric Cancer. NCT07655661 · ClinicalTrials.gov ↗ · Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma	Phase 2	Not yet open	Ming Liu	China
Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study NCT07685704 · ClinicalTrials.gov ↗ · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, HER2-positive Gastric Cancer	Phase 2	Not yet open	Zhifeng Zhao, PhD	China
Sonrotoclax, Glofitamab, Gemcitabine, and Oxaliplatin for Relapsed or Refractory Large B-Cell Lymphoma NCT07774234 · ClinicalTrials.gov ↗ · Large B-Cell Lymphoma (LBCL), High-grade B-cell Lymphoma	Phase 2	Not yet open	The First Affiliated Hospital of Soochow University	China
A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation NCT07814417 · ClinicalTrials.gov ↗ · Colorectal Neoplasms	Phase 2	Not yet open	Eli Lilly and Company	USA, China, Spain
A Single-Arm Study of QL1706 Combined With DOS as Neoadjuvant Therapy for Locally Advanced Gastric/GEJ Adenocarcinoma NCT07828873 · ClinicalTrials.gov ↗ · Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma	Phase 2	Not yet open	The First Affiliated Hospital of Zhengzhou University	China
SCRT Combined With CAPOX and PD-1/CTLA4 Antibody for Early-stage Low Rectal Cancer NCT07837362 · ClinicalTrials.gov ↗ · Early Low Rectal Cancer	Phase 2	Not yet open	Fudan University	China
A Prospective, Biomarker-Stratified Phase 2 Study: β-Hydroxybutyrate as a Predictive Biomarker for Short-Course Radiotherapy Followed by Chemotherapy Plus PD-1 Inhibitor Versus Chemotherapy Alone in Locally Advanced Rectal Cancer NCT07847229 · ClinicalTrials.gov ↗ · Rectal Cancer, Radiotherapy, Immunotherapy	Phase 2	Not yet open	Tao Zhang	China
Exploring the Efficacy of Ferrous Sulfate/Ferrous Succinate Combined With Serplulimab and SOX Regimen in Neoadjuvant Therapy for Gastric Cancer: A Prospective Cohort Study NCT07872696 · ClinicalTrials.gov ↗ · Gastric Neoplasms	Phase 2	Not yet open	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	China
Glofitamab Plus Gemcitabine and Oxaliplatin (GemOx) in Relapsed or Refractory Primary and Secondary Central Nervous System Lymphoma NCT07888621 · ClinicalTrials.gov ↗ · PCNSL (Primary CNS Lymphoma), Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma (SCNSL)	Phase 2	Not yet open	The First Affiliated Hospital with Nanjing Medical University	China
FOLFOX Plus Lenvatinib Adjuvant Therapy for Hepatocellular Carcinoma Post-Liver Transplantation NCT06409637 · ClinicalTrials.gov ↗ · Liver Cancer, Liver Transplant	Phase 1/2	Not yet open	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	China
SHR - A1811 Injection in the Treatment of Platinum-sensitive Recurrent Ovarian Cancer NCT06990516 · ClinicalTrials.gov ↗ · Ovarian Cancer	Phase 1/2	Not yet open	Tongji Hospital	China
A Study of MRG007 Combination Therapy for Advanced Colorectal Cancer NCT07737600 · ClinicalTrials.gov ↗ · Advanced Colorectal Cancer	Phase 1/2	Not yet open	Lepu Biopharma Co., Ltd	China
A Study of BL-M08D1 in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell Lymphoma NCT07818499 · ClinicalTrials.gov ↗ · Diffuse Large B-Cell Lymphoma	Phase 1/2	Not yet open	Sichuan Baili Pharmaceutical Co., Ltd	China
TQB2922 Injection Given Under the Skin With Chemotherapy as Initial Treatment for Colorectal Cancer That Has Spread NCT07844187 · ClinicalTrials.gov ↗ · Colorectal Neoplasms	Phase 1/2	Not yet open	Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd	China
A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors NCT06963502 · ClinicalTrials.gov ↗ · Advanced Solid Tumors, Colorectal Cancer, Non-Small Cell Lung Cancer	Phase 1	Not yet open	Jiangsu Hansoh Pharmaceutical Co., Ltd	China
A Prospective Study on the Clinical Value of Skin Test for Oxaliplatin Hypersensitivity Reaction and Its Correlation With Biomarkers NCT07613905 · ClinicalTrials.gov ↗ · Hypersensitivity Reaction	Not applicable	Not yet open	Fujian Cancer Hospital	China
Sintilimab Combined With Chemoradiotherapy as Neoadjuvant Therapy for Locally Advanced Gastroesophageal Junction Cancer NCT07859410 · ClinicalTrials.gov ↗ · Gastroesophageal Junction Adenocarcinoma	Not applicable	Not yet open	Anhui Medical University	China
Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer NCT07441369 · ClinicalTrials.gov ↗ · Liver Metastases From Colorectal Cancer (mCRC)	Phase 2	By invitation	Fudan University	China
Clinical Efficacy of Pucotenlimab Combined With Lenvatinib and SOX Versus SOX Alone in Patients With HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma NCT07356466 · ClinicalTrials.gov ↗ · Gastric (Stomach) Cancer	Early Phase 1	By invitation	Fujian Medical University	China
Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer NCT01081262 · ClinicalTrials.gov ↗ · Borderline Ovarian Mucinous Tumor, Ovarian Mucinous Cystadenocarcinoma, Recurrent Fallopian Tube Carcinoma	Phase 3	Active, closed	National Cancer Institute (NCI)	Mexico
FOLFOX or CAPOX Perioperative Chemotherapy Versus Postoperative Chemotherapy for Locally Advanced Colon Cancer (OPTICAL) NCT02572141 · ClinicalTrials.gov ↗ · Colon Cancer	Phase 3	Active, closed	Sun Yat-sen University	China
Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair NCT02912559 · ClinicalTrials.gov ↗ · Colon Adenocarcinoma, DNA Repair Disorder, Lynch Syndrome	Phase 3	Active, closed	National Cancer Institute (NCI)	Germany, Mexico, Israel
Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study NCT02997228 · Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7	Phase 3	Active, closed	National Cancer Institute (NCI)	Mexico
Paediatric Hepatic International Tumour Trial NCT03017326 · Hepatoblastoma, Carcinoma, Hepatocellular	Phase 3	Active, closed	University of Birmingham	Ireland, Germany, France, Spain, Netherlands, Belgium, Poland, Switzerland, Austria, Czechia, Norway, Israel
A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer. NCT03504397 · Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer	Phase 3	Active, closed	Astellas Pharma Global Development, Inc	UK, USA, China, Germany, France, Spain, Italy, Belgium, Poland, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery NCT03533582 · ClinicalTrials.gov ↗ · Childhood Hepatocellular Carcinoma, Childhood Malignant Liver Neoplasm, Fibrolamellar Carcinoma	Phase 3	Active, closed	Children's Oncology Group	Canada, Mexico, Australia, Israel
A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW). NCT03653507 · Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer	Phase 3	Active, closed	Astellas Pharma Global Development, Inc	Ireland, UK, USA, China, Spain, Netherlands, Portugal, Turkey, Canada, Mexico, Japan, South Korea, Taiwan
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) NCT04008030 · Metastatic Colorectal Cancer	Phase 3	Active, closed	Bristol-Myers Squibb	Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Austria, Czechia, Norway, Turkey, Canada, Brazil, Japan, Australia
Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer NCT04094688 · ClinicalTrials.gov ↗ · Colorectal Adenocarcinoma	Phase 3	Active, closed	Alliance for Clinical Trials in Oncology	Mexico, Israel, Egypt
Short RT Versus RCT,Followed by Chemo and Organ Preservation for Interm and High-risk Rectal Cancer Patients NCT04246684 · ClinicalTrials.gov ↗ · Rectal Cancer Stage III	Phase 3	Active, closed	Prof. Dr. med. Claus Rödel	Germany
Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer NCT04340141 · ClinicalTrials.gov ↗ · Pancreatic Adenosquamous Carcinoma, Resectable Pancreatic Adenocarcinoma, Stage I Pancreatic Cancer AJCC v8	Phase 3	Active, closed	Alliance for Clinical Trials in Oncology	Canada, Mexico
Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma NCT04384484 · Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma	Phase 3	Active, closed	ADC Therapeutics S.A	UK, USA, China, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Czechia, Turkey, Canada, Brazil, Mexico, Japan, Israel
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma NCT04408638 · Diffuse Large B-cell Lymphoma	Phase 3	Active, closed	Hoffmann-La Roche	UK, USA, China, Germany, France, Spain, Belgium, Denmark, Poland, Switzerland, South Korea, Taiwan, Australia
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer NCT04607421 · Neoplasms	Phase 3	Active, closed	Pfizer	UK, USA, India, China, Germany, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Czechia, Norway, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia
A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer NCT04854668 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer	Phase 3	Active, closed	Chia Tai Tianqing Pharmaceutical Group Co., Ltd	China, Japan
Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE NCT04919226 · Neuroendocrine Tumors	Phase 3	Active, closed	ITM Solucin GmbH	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Australia
Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer NCT04927780 · ClinicalTrials.gov ↗ · Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Adenocarcinoma	Phase 3	Active, closed	Erasmus Medical Center	Netherlands, Sweden
A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer) NCT05144854 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 3	Active, closed	Ono Pharmaceutical Co., Ltd	China, Japan, South Korea, Taiwan
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers NCT05152147 · Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma	Phase 3	Active, closed	Jazz Pharmaceuticals	Ireland, UK, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia
A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma NCT05171647 · Non-Hodgkin Lymphoma	Phase 3	Active, closed	Hoffmann-La Roche	USA, China, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Israel
Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer NCT05171660 · ClinicalTrials.gov ↗ · Colorectal Cancer Stage IV	Phase 3	Active, closed	Second Affiliated Hospital, Zhejiang University, School of Medicine	China
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66) NCT05239741 · ClinicalTrials.gov ↗ · Colorectal Neoplasms	Phase 3	Active, closed	Merck Sharp & Dohme LLC	China
Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) NCT05771480 · Biliary Tract Cancer	Phase 3	Active, closed	AstraZeneca	USA, Germany, France, Spain, Italy, Japan, South Korea, Singapore
ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma NCT06206733 · ClinicalTrials.gov ↗ · Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma	Phase 3	Active, closed	AskGene Pharma, Inc	China
Node-sparing Short-Course Radiation Combined With CAPOX and Tislelizumab for MSS Rectal Cancer NCT06507371 · ClinicalTrials.gov ↗ · Rectal Cancer	Phase 3	Active, closed	Sir Run Run Shaw Hospital	China
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma NCT06508658 · Diffuse Large B-Cell Lymphoma	Phase 3	Active, closed	Genmab	UK, USA, China, France, Netherlands, Belgium, Poland, Czechia, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) NCT06625320 · Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma	Phase 3	Active, closed	Revolution Medicines, Inc	USA, Germany, France, Spain, Italy, Japan
A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma NCT06929624 · ClinicalTrials.gov ↗ · Diffuse Large B-cell Lymphoma	Phase 3	Active, closed	Suzhou Suncadia Biopharmaceuticals Co., Ltd	China
Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test NCT07340567 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 3	Active, closed	UNICANCER	France, Sweden
Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma NCT01924819 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 2/3	Active, closed	Australasian Gastro-Intestinal Trials Group	Germany, France, Spain, Belgium, Czechia, Canada, Australia, Israel
Compare Neoadjuvant DOS Combined With Toripalimab Versus SOX Combined With Toripalimab in Locally Advanced Gastric Adenocarcinoma NCT03691454 · ClinicalTrials.gov ↗ · Gastric Adenocarcinoma	Phase 2/3	Active, closed	Peking University	China
Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery NCT04068103 · ClinicalTrials.gov ↗ · Colon Adenocarcinoma, Stage IIA Colon Cancer AJCC v8	Phase 2/3	Active, closed	NRG Oncology	Canada, Mexico
Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer NCT04137107 · ClinicalTrials.gov ↗ · Stage II Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8	Phase 2/3	Active, closed	Alliance for Clinical Trials in Oncology	Mexico, Israel
Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response NCT05610163 · Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Locally Advanced Rectal Adenocarcinoma	Phase 2/3	Active, closed	Alliance for Clinical Trials in Oncology	Mexico, Israel
A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer NCT05980481 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 2/3	Active, closed	RemeGen Co., Ltd	China
Radiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer NCT00335816 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 2	Active, closed	Memorial Sloan Kettering Cancer Center	Canada
Multicentric Randomised Trial for Resectable Gastric Cancer NCT02931890 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 2	Active, closed	The Netherlands Cancer Institute	Netherlands
LEAn Body Mass Normalization of OXaliplatin Based Chemotherapy NCT03255434 · ClinicalTrials.gov ↗ · Stage III Colon Cancer	Phase 2	Active, closed	Institut du Cancer de Montpellier - Val d'Aurelle	France
Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness NCT03421288 · ClinicalTrials.gov ↗ · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma	Phase 2	Active, closed	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	Germany, Switzerland
Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA) NCT03448835 · ClinicalTrials.gov ↗ · Stomach Cancer, Gastro Esophageal Junction Cancer	Phase 2	Active, closed	The Netherlands Cancer Institute	Netherlands
Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM NCT03493048 · ClinicalTrials.gov ↗ · Colorectal Cancer, Liver Metastases	Phase 2	Active, closed	Sun Yat-sen University	China
A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer NCT03505320 · Pharmacokinetics of Zolbetuximab, Gastric Cancer, Gastro-esophageal Junction (GEJ) Cancer	Phase 2	Active, closed	Astellas Pharma Global Development, Inc	USA, France, Italy, Japan, South Korea, Taiwan
Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer NCT03764553 · ClinicalTrials.gov ↗ · Esophageal Cancer	Phase 2	Active, closed	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	Netherlands
Irinotecan-based Triplet (FOLFOXIRI) as Perioperative Treatment in Resectable Gastric and Gastroesophageal Junction Adenocarcinoma. NCT03773367 · ClinicalTrials.gov ↗ · Resectable Gastric and Gastroesophageal Junction Adenocarcinoma	Phase 2	Active, closed	Lund University Hospital	Sweden, Norway
Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer NCT04245865 · ClinicalTrials.gov ↗ · Colorectal Cancer Metastatic	Phase 2	Active, closed	Vejle Hospital	Denmark
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) NCT04379596 · Gastric Cancer	Phase 2	Active, closed	AstraZeneca	UK, USA, China, Germany, Spain, Italy, Netherlands, Poland, Canada, Brazil, Japan, South Korea, Taiwan
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers NCT04430738 · Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma	Phase 2	Active, closed	Seagen, a wholly owned subsidiary of Pfizer	USA, Mexico, Japan
An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric Cancer NCT04745988 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 2	Active, closed	National Cancer Center Hospital East	Japan
A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer NCT05026905 · ClinicalTrials.gov ↗ · Phase II, Open-label, Parallel 2-arm, Multi-center	Phase 2	Active, closed	National Health Research Institutes, Taiwan	China, Taiwan
Short-course Radiotherapy Followed by Consolidation Chemotherapy. 2021-001206-29 NCT05253846 · ClinicalTrials.gov ↗ · Locally Advanced Rectal Cancer	Phase 2	Active, closed	Gruppo Oncologico del Nord-Ovest	Italy
A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer NCT05382442 · Metastatic Colorectal Cancer	Phase 2	Active, closed	Akeso	USA, China
Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer NCT05476796 · ClinicalTrials.gov ↗ · Gastric Adenocarcinoma, Esophagus Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma	Phase 2	Active, closed	UNICANCER	France
METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin NCT05504252 · ClinicalTrials.gov ↗ · Colorectal Adenocarcinoma, Mucinous Adenocarcinoma, Signet Ring Cell Adenocarcinoma	Phase 2	Active, closed	University Hospital, Akershus	Norway
Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial) NCT05564403 · ClinicalTrials.gov ↗ · Advanced Biliary Tract Carcinoma, Advanced Gallbladder Carcinoma, Advanced Intrahepatic Cholangiocarcinoma	Phase 2	Active, closed	National Cancer Institute (NCI)	Mexico
CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Microsatellite Stable Locally Advanced Rectal Cancer NCT05585814 · ClinicalTrials.gov ↗ · Locally Advanced Rectal Cancer	Phase 2	Active, closed	Shanghai Changzheng Hospital	China
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors NCT05945823 · Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer	Phase 2	Active, closed	Taiho Oncology, Inc	USA, Germany, France, Spain
NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer NCT06094140 · ClinicalTrials.gov ↗ · Pancreatic Cancer	Phase 2	Active, closed	Australasian Gastro-Intestinal Trials Group	Australia
Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer NCT06124378 · ClinicalTrials.gov ↗ · Colonic Neoplasms, Neoadjuvant Therapy, Immune Checkpoint Inhibitors	Phase 2	Active, closed	First Affiliated Hospital of Guangxi Medical University	China
Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer NCT06247956 · ClinicalTrials.gov ↗ · Advanced Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma	Phase 2	Active, closed	Suzhou Suncadia Biopharmaceuticals Co., Ltd	China
A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer) NCT06256328 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 2	Active, closed	Ono Pharmaceutical Co., Ltd	China, Japan, South Korea, Taiwan
Short-course Radiotherapy or Long-course Chemoradiation Followed by mFOLFOXIRI Consolidation Chemotherapy for Organ Preservation in Low Rectal Cancer NCT06417476 · ClinicalTrials.gov ↗ · Rectal Neoplasms	Phase 2	Active, closed	Pei-Rong Ding	China
Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma NCT06447636 · ClinicalTrials.gov ↗ · Gastric Cancer, Gastro Esophageal Junction Cancer	Phase 2	Active, closed	Fudan University	China
Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction NCT06576921 · ClinicalTrials.gov ↗ · Stomach Neoplasms, Immune Checkpoint Inhibitors	Phase 2	Active, closed	Xijing Hospital	China
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma NCT06628310 · Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma	Phase 2	Active, closed	AbbVie	UK, USA, China, Germany, Spain, Belgium, Canada, Japan, Taiwan, Israel
Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma NCT06914687 · ClinicalTrials.gov ↗ · Gastric Adenocarcinoma, Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma, Peritoneal Metastasis	Phase 2	Active, closed	Fudan University	China
A Single-arm, Multicenter Exploratory Clinical Trial of Anlotinib Combined With TQB2450 and the SOX Regimen as First-line Treatment for Advanced Gastric Cancer With Low PD-L1 Expression NCT06939452 · ClinicalTrials.gov ↗ · Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma	Phase 2	Active, closed	Yongxu Jia	China
Perioperative Treatment With TAS-102 in Combination With Oxaliplatin for Locally Advanced Rectal Cancer NCT07090031 · ClinicalTrials.gov ↗ · EFS, pCR Rate	Phase 2	Active, closed	Qingdao Central Hospital	China
A Randomized Controlled Study of Serplulimab Combined With Chemotherapy for Locally Advanced Gastric Adenocarcinoma NCT07257575 · ClinicalTrials.gov ↗ · Gastric Cancer Stage III	Phase 2	Active, closed	Guangdong Provincial People's Hospital	China
Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma NCT07480850 · ClinicalTrials.gov ↗ · Refractory Diffuse Large B-Cell Lymphoma (DLBCL)	Phase 2	Active, closed	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
Iparomlimab and Tuvonralimab Injection (QL1706) Combined With DOS as Neoadjuvant Therapy for Locally Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction NCT07776639 · ClinicalTrials.gov ↗ · Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma	Phase 2	Active, closed	Yongxu Jia	China
CapeOx Combined With Anti-PD1 Antibody Plus Dihydroartemisinin as Neoadjuvant or Conversion Therapy for Microsatellite Stable Locally Advanced and Metastatic Colorectal Cancer NCT07801352 · ClinicalTrials.gov ↗ · Locally Advanced Colorectal Cancer, Metastatic Colorectal Cancer	Phase 2	Active, closed	Shanghai Changzheng Hospital	China
A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors NCT04495296 · ClinicalTrials.gov ↗ · Advanced Cancer	Phase 1/2	Active, closed	Transcenta Therapeutics (Hangzhou) Co., Ltd	China
Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer NCT04821284 · ClinicalTrials.gov ↗ · Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8	Phase 1/2	Active, closed	Flemming Forsberg	Norway
Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in PMMR/MSS CRLM Patients NCT04940546 · ClinicalTrials.gov ↗ · Colorectal Cancer Metastatic	Phase 1/2	Active, closed	Sun Yat-sen University	China
A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer NCT05846867 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 1/2	Active, closed	Akeso	China
Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors NCT06771622 · ClinicalTrials.gov ↗ · Solid Cancer	Phase 1/2	Active, closed	FBD Biologics Limited	China
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. NCT05355701 · Melanoma, Non-Small-Cell Lung Cancer, Thyroid Cancer	Phase 1	Active, closed	Pfizer	USA, Canada, Israel
A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced or Metastatic Solid Tumors NCT05502393 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1	Active, closed	Shanghai Junshi Bioscience Co., Ltd	China
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers NCT05891171 · ClinicalTrials.gov ↗ · Advanced Cancer, Advanced Malignancies, Bladder Cancer	Phase 1	Active, closed	Arcus Biosciences, Inc	USA, Taiwan, Australia
ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer NCT06328738 · HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Positive Solid Tumors	Phase 1	Active, closed	Enliven Therapeutics	USA, France, Spain, Italy, Netherlands, Belgium, South Korea
An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer NCT06532344 · ClinicalTrials.gov ↗ · Metastatic Pancreatic Cancer	Phase 1	Active, closed	Ono Pharmaceutical Co., Ltd	Japan
The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer NCT06540261 · ClinicalTrials.gov ↗ · Unresectable Colorectal Cancer	Phase 1	Active, closed	Ono Pharmaceutical Co., Ltd	Japan
A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors NCT06544655 · Advanced Solid Tumors	Phase 1	Active, closed	Bristol-Myers Squibb	USA, Canada, Australia
Study of ONO-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal Cancer NCT06547385 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 1	Active, closed	Ono Pharmaceutical Co., Ltd	Japan
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors NCT06586515 · Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer	Phase 1	Active, closed	Eli Lilly and Company	Ireland, USA, China, Germany, France, Spain, Italy, Canada, Japan
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors NCT06607185 · ClinicalTrials.gov ↗ · Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer	Phase 1	Active, closed	Eli Lilly and Company	USA, Germany, France, Spain, Italy, Belgium, Japan, Taiwan
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma NCT06624085 · Lymphoma	Phase 1	Active, closed	Hoffmann-La Roche	USA
First-line Combination of Capecitabine and Oxaliplatin Plus Bevacizumab in Elderly Patients With Metastatic Colorectal Cancer NCT03451370 · ClinicalTrials.gov ↗ · Elderly Metastatic Colorectal Cancer Patients	Observational	Active, closed	Istituto Oncologico Veneto IRCCS	Italy

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Oxaliplatin in the EU trials register (CTIS)

16 trials · 1 in Ireland

Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Oxaliplatin. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.

Study	Phase	Status	Sponsor	Countries
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer (HARMONi-GI3) 2025-521587-35-00 · Neoplasms	Phase 3	Ongoing	Summit Therapeutics Inc	Ireland + 8 more
METIMMOX-3: Using Tumor Mutational Status as Selection Biomarker for First-Line Therapy with Short-Course Oxaliplatin-Based Chemotherapy and Bevacizumab Alternating with Tislelizumab in Metastatic MSS/pMMR Colorectal Cancer 2026-526317-29-00 · CTIS ↗ · Digestive System Diseases	Phase 2	Authorised	Akershus University Hospital	Norway
A Phase 3, Global, Multi-center, Double-blind, Randomized Study of ASP2138 plus Chemotherapy (CAPOX or mFOLFOX6) with Pembrolizumab vs Placebo plus Chemotherapy with or without Pembrolizumab in First-line Treatment of Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma in Participants Whose Tumors Are HER2-negative and Claudin (CLDN) 18.2-positive 2025-524557-14-00 · CTIS ↗ · Neoplasms	Phase 3	Authorised	Astellas Pharma Global Development Inc	Poland, Romania, Spain + 6 more
A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, With and Without an Anti-EGFR Antibody, and With an Anti-EGFR Antibody and Chemotherapy, in Patients With Metastatic KRAS G12D-Mutated Colorectal Adenocarcinoma (TARGET-D 203) 2026-526473-42-00 · CTIS ↗ · Neoplasms	Phase 2	Authorised	Verastem Inc	Italy, Spain, France + 2 more
A Randomized, Open-label, Phase 3 Trial of Petosemtamab in Combination With mFOLFOX6 or FOLFIRI Versus Cetuximab in Combination With mFOLFOX6 or FOLFIRI as First-line Treatment for Participants With RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer. 2026-525883-17-00 · CTIS ↗ · Neoplasms	Phase 3	Authorised	Genmab A/S	Italy, Poland, Greece + 11 more
A phase II, open-label, randomized, multi-center study comparing the efficacy and safety of Sacituzumab govitecan versus investigator's choice in patients with cancer of unknown primary (CUP) who are relapsed after or refractory to platinum-based chemotherapy (SACICUP) 2025-523055-55-00 · Neoplasms	Phase 2	Authorised	Universitaetsklinikum Heidelberg AöR	Germany
Phase II randomized trial evaluating modified FOLFIRINOX and FOLFOX in the treatment of locally advanced or metastatic small bowel adenocarcinoma [FIRE-12] 2025-524131-39-00 · Digestive System Diseases	Phase 3	Ongoing	Charite Universitaetsmedizin Berlin KöR	Germany
COLOVERT – Conversion therapy in colorectal cancer with peritoneal metastases not amenable to upfront cytoreductive surgery and HIPEC: a phase II “pick-the-winner” open-label randomized trial 2026-526122-41-00 · Not possible to specify	Phase 2	Authorised	Uppsala University Hospital	Sweden
Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan in Combination with FOLFOX Compared to Standard of Care in Subjects with First-Line Metastatic Pancreatic Ductal Adenocarcinoma - AndroMETa-PDAC-288 2025-522563-15-00 · Neoplasms	Phase 3	Authorised	AbbVie Deutschland GmbH & Co. KG	Portugal, Spain, France + 3 more
PACHA-02_Postoperative hepatic arterial chemotherapy after resection of colorectal liver metastases in patients at high risk of recurrence 2025-523913-27-00 · CTIS ↗ · Neoplasms	Phase 3	Authorised	Unicancer	France
A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer 2025-523735-19-00 · CTIS ↗ · Neoplasms	Phase 3	Ongoing	Incyte Corp	Poland, France, Denmark + 7 more
TAILOR-PANC: Molecularly Tailored Therapy versus Standard Care in Advanced Pancreatic Cancer (DPCG-02) 2025-522431-34-00 · CTIS ↗ · Neoplasms	Phase 2	Authorised	Region Hovedstaden	Denmark
C6461003 - AN INTERVENTIONAL, PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER 2025-523521-18-00 · CTIS ↗ · Neoplasms	Phase 3	Ongoing	Pfizer Inc	Spain, Belgium, France + 5 more
ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemotherapy Versus Bevacizumab in Combination with Chemotherapy in Participants with Previously Untreated, Unresectable, or Metastatic Colorectal Cancer 2025-523224-45-00 · CTIS ↗ · Neoplasms	Phase 3	Ongoing	Bristol-Myers Squibb Services Unlimited Company	Sweden, Czechia, Belgium + 8 more
A phase 2, single arm, open label, study on the safety and feasibility of Liver Isolated Oxaliplatin (LIOX) delivered via arterial access device for treatment of liver metastasis in colorectal cancer patients 2025-523261-25-00 · CTIS ↗ · Therapeutics	Phase 2	Authorised	UZ Leuven	Belgium
NACRE 2_Randomized phase III study evaluating two treatment strategies for locally advanced rectal cancer in patients ≥75 years old 2025-521619-37-00 · CTIS ↗ · Neoplasms	Phase 3	Authorised	Unicancer	France

Oxaliplatin across our data

Ireland · EU · US

The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.

Licensed in Ireland (HPRA)

2 single-substance products containing Oxaliplatin on the HPRA medicines list.

Oxaliplatin 5 mg/ml Concentrate for Solution for InfusionAccord Healthcare Ireland Ltd. · PA2315/114/001 · Marketed
Oxaliplatin 5 mg/ml concentrate for solution for infusionFresenius Kabi Deutschland GmbH · PA2059/049/001 · Marketed

All 2 Irish products →

Supply shortages

Oxaliplatin InjectionUS (FDA) · Resolved · updated 29 Jun 2026

EU shortages US shortages German shortages

Conditions studied with Oxaliplatin

302 conditions

Gastric Cancer30 Colorectal Cancer25 Gastroesophageal Junction Adenocarcinoma14 Gastric Adenocarcinoma12 Rectal Cancer11 Locally Advanced Rectal Cancer10 Metastatic Colorectal Cancer9 Pancreatic Cancer8 Pancreatic Ductal Adenocarcinoma7 Colorectal Neoplasms7 Biliary Tract Cancer7 Advanced Solid Tumors7

All 302 conditions

Condition (as registered)	Trials
Gastric Cancer	30
Colorectal Cancer	25
Gastroesophageal Junction Adenocarcinoma	14
Gastric Adenocarcinoma	12
Rectal Cancer	11
Locally Advanced Rectal Cancer	10
Metastatic Colorectal Cancer	9
Pancreatic Cancer	8
Pancreatic Ductal Adenocarcinoma	7
Colorectal Neoplasms	7
Biliary Tract Cancer	7
Advanced Solid Tumors	7
Neoadjuvant Therapy	6
Esophageal Adenocarcinoma	5
HER2-positive Gastric Cancer	5
Colorectal Cancer Metastatic	5
Gastroesophageal Adenocarcinoma	4
Esophageal Cancer	4
Stomach Neoplasms	4
Advanced Solid Tumor	4
Gastroesophageal Junction (GEJ) Adenocarcinoma	4
Immunotherapy	4
Radiotherapy	4
Cholangiocarcinoma	4
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer	3
Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer	3
Metastatic Gastric Adenocarcinoma or Cancer	3
Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma	3
Colon Adenocarcinoma	3
Rectal Adenocarcinoma	3
Metastatic Pancreatic Ductal Adenocarcinoma	3
PDAC	3
Diffuse Large B-Cell Lymphoma	3
Metastatic Colorectal Cancer (CRC)	3
Metastatic Gastric Adenocarcinoma	3
PDAC - Pancreatic Ductal Adenocarcinoma	3
Solid Tumor	3
Advanced Cancer	3
Gastric or Gastroesophageal Junction Adenocarcinoma	3
Immune Checkpoint Inhibitors	3
Early Low Rectal Cancer	3
Colon Cancer	3
Chemotherapy	3
Adenocarcinoma of the Stomach	3
Adenocarcinoma of Esophagogastric Junction	3
Intrahepatic Cholangiocarcinoma	3
Colorectal Adenocarcinoma	3
Stage II Pancreatic Cancer AJCC v8	3
Non-small Cell Lung Cancer	2
Hepatoblastoma	2
Gastric Neoplasms	2
Cancer	2
Solid Tumors	2
DLBCL	2
Metastatic Pancreatic Cancer	2
Diffuse Large B-cell Lymphoma	2
Metastatic Colorectal Adenocarcinoma	2
Gastroesophageal-junction Cancer	2
Esophageal Squamous Cell Carcinoma	2
Colorectal Carcinoma	2
Peritoneal Metastases	2
Gall Bladder Cancer	2
Ovarian Cancer	2
Colonic Neoplasms	2
Diffuse Large B Cell Lymphoma (DLBCL)	2
Gastric (Stomach) Cancer	2
Locally Advanced Gastric Cancer	2
Liver Metastases	2
Advanced Colorectal Cancer	2
Rectal Cancer Stage III	2
Hepatocellular Carcinoma (HCC)	2
Relapsed/Refractory Diffuse Large B-Cell Lymphoma	2
Gastric Cancer (GC)	2
pMMR	2
Locally Advanced Rectal Carcinoma	2
Gastro Esophageal Junction Cancer	2
Peritoneal Carcinomatosis	2
Colo-rectal Cancer	2
Colon Carcinoma	2
Advanced Esophageal Adenocarcinoma	2
Advanced Gastric Adenocarcinoma	2
Resectable Pancreatic Adenocarcinoma	2
Locally Advanced / Metastatic Solid Tumors	1
Carcinoma, Hepatocellular	1
Relapsed Diffuse Large B-Cell Lymphoma	1
Refractory Diffuse Large B-Cell Lymphoma	1
Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma	1
Neuroendocrine Tumors	1
Neoplasms	1
Metastatic Pancreatic Adenocarcinoma	1
Pancreatic Cancer Metastatic	1
Carcinoma, Non-Small-Cell Lung	1
Advanced Breast Cancer	1
Metastatic Breast Cancer (HR+/ HER2-)	1
Monoclonal Antibody	1
Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma	1
Malignant Neoplam	1
Lymphoma	1
Melanoma	1
Non-Small-Cell Lung Cancer	1
Thyroid Cancer	1
Glioma	1
Locally Advanced or Metastatic Solid Tumors	1
Non-Hodgkin Lymphoma	1
Malignant Neoplasm	1
Advanced Malignancies	1
Bladder Cancer	1
Cervical Cancer	1
Advanced Unresectable Gastric Adenocarcinoma	1
Advanced Gastroesophageal Adenocarcinoma	1
GEJ Adenocarcinoma	1
Gastroesophageal Junction	1
Esophageal Neoplasms	1
Pancreatic Adenocarcinoma	1
Locally Advanced Solid Tumor	1
Advanced or Metastatic Colorectal Cancer	1
Metastatic Cancer	1
Pharmacokinetics of Zolbetuximab	1
Gastro-esophageal Junction (GEJ) Cancer	1
Pharmacokinetics of Oxaliplatin	1
HER2-positive Breast Cancer	1
HER2 Positive Solid Tumors	1
HER2 Amplification	1
Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer	1
Esophageal Squamous Cell Cancer	1
Siewert Type 1 GEJ Cancer	1
Gastric Cancer Stage IV	1
Metastatic Colorectal Carcinoma	1
Advanced Solid Tumour	1
Esophagogastric Junction Cancer	1
Resectable Gastric or Gastroesophageal Junction Adenocarcinoma	1
Relapsed/Refractory Large B-Cell Lymphoma	1
Locally Recurrent Colorectal Cancer	1
Colorectal Liver Metastases	1
First-line Treatment	1
Locally Advanced Gastroesophageal Junction Adenocarcinoma	1
Chemotherapy Effect	1
Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma	1
Diffuse Large Cell B-lymphoma	1
Liver Metastases From Colorectal Cancer (mCRC)	1
Gastrointestinal Cancer	1
CRC, Colorectal Cancer	1
Immunotherapy Gastrict Cancer	1
Rectal Cancer Patients	1
Rectal Cancer Stage II	1
Linitis Plastica of Stomach	1
Nanoliposomal Irinotecan	1
Cadonilimab	1
Oxaliplatin	1
Capecitabine	1
Adenocarcinoma	1
Advanced Pancreatic Cancer	1
Second Line Treatment	1
Tyrosine Kinase Inhibitor	1
Epstein-Barr Virus-Associated Gastric Carcinoma	1
Locally Advanced Pancreatic Cancer	1
Locally Advanced Colorectal Cancer	1
Pancreatic Cancer Metastatic to Liver	1
Colon Neoplasm	1
Gastroesophageal Junction Adenocarcinoma (Siewert II-III)	1
Previously AG Chemotherapy Treated Pancreatic Cancer	1
First-line Treatment of Metastatic Pancreatic Cancer	1
Gastric Cancer Metastatic to Regional Lymph Nodes	1
Advanced Pancreatic Cancer (Part 1)	1
Advanced Solid Tumors Cancer	1
RAS Mutation	1
Advanced Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma	1
Low Rectal Cancer	1
DLBCL - Diffuse Large B Cell Lymphoma	1
RCT	1
Proficient Mismatch Repair	1
Resectable Gastric/Gastroesophageal Junction Adenocarcinoma	1
Non-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Melanoma and Other Solid Tumor	1
GC/GEJC	1
Locally Advanced Unresectable or Metastatic Gastric Cancer	1
Locally Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma	1
Extranodal NK/T-cell Lymphoma	1
Colorectal Cancer Stage IV	1
Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma	1
Locally Recurrent Rectal Cancer	1
Hepatocellular Carcinoma	1
Adjuvant Chemotherapy	1
Stage 3 Cancer	1
Docetaxel	1
Esophagogastric Junction Adenocarcinoma	1
Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma	1
Peritoneal Metastasis	1
MSS	1
MSI-L	1
Colorectal Cancer Liver Metastasis	1
Total Neoadjuvant Therapy	1
Malignant Biliary Tract Tumors	1
PCNSL (Primary CNS Lymphoma)	1
Central Nervous System Lymphoma	1
Secondary Central Nervous System Lymphoma (SCNSL)	1
Gastric (Cardia, Body) Cancer	1
Stomach Adenocarcinoma	1
Locally Advanced	1
Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma	1
CRC	1
NK/T Cell Lymphoma Nos	1
Locally Advanced Rectal Cancer (LARC)	1
MSS (Microsatellite Stable)	1
Resectable Colon Cancer	1
MSI-H/dMMR Colorectal Cancer	1
Gastric Carcinoma	1
Rectal Neoplasms	1
Adjuvant Therapy	1
Large B-Cell Lymphoma (LBCL)	1
High-grade B-cell Lymphoma	1
Refractory Diffuse Large B-Cell Lymphoma (DLBCL)	1
Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type	1
Non-Small Cell Lung Cancer	1
Advanced Malignant Solid Tumors	1
Locally Advanced Colon Cancer	1
Gallbladder Cancer	1
Advanced Solid Tumor Cancer	1
Rectal Cancer, Adenocarcinoma	1
Locally Advanced Rectal Cancer With Liver Metastases	1
Metastatic Gastroesophageal Junction Adenocarcinoma	1
Gastric Cancer Stage III	1
Recurrent Rectal Cancer	1
EFS	1
pCR Rate	1
Liver Cancer	1
Liver Transplant	1
Mismatch Repair Deficiency	1
Phase II, Open-label, Parallel 2-arm, Multi-center	1
Solid Cancer	1
Hypersensitivity Reaction	1
Metastatic Gastric Cancer	1
Unresectable Gastric Carcinoma	1
Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma	1
Hilar Cholangiocarcinoma	1
Bile Duct Cancer	1
Bile Duct Carcinoma	1
DNA Repair Disorder	1
Lynch Syndrome	1
Stage III Colon Cancer AJCC v8	1
Colon Cancer Stage II	1
Colon Cancer Stage III	1
Metastatic Gastroesophageal Adenocarcinoma	1
DPD Deficiency	1
Metastatic Colorectal Carcinoma (mCRC)	1
Metastatic Esophageal Adenocarcinoma	1
Biliary Tract Cancer (BTC)	1
Stage III Colon Cancer	1
Lymphoma, Non-Hodgkin	1
Esophagus Adenocarcinoma	1
Metastatic Colorectal Cancer (mCRC)	1
Pancreatic Adenocarcinoma Advanced or Metastatic	1
Elderly Metastatic Colorectal Cancer Patients	1
Ampullary Adenocarcinoma	1
Resectable MMR-deficient Solid Tumors	1
Resectable MMR-proficient Solid Tumors	1
Stomach Cancer	1
Resectable Gastric and Gastroesophageal Junction Adenocarcinoma	1
Peritoneum Cancer	1
Mucinous Adenocarcinoma	1
Signet Ring Cell Adenocarcinoma	1
Locally Advanced Pancreatic Ductal Adenocarcinoma	1
Stage IIA Pancreatic Cancer AJCC v8	1
Lung Metastases	1
Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma	1
Stage III Pancreatic Cancer AJCC v8	1
Stage IV Pancreatic Cancer AJCC v8	1
Stage IIA Colon Cancer AJCC v8	1
Childhood Hepatocellular Carcinoma	1
Childhood Malignant Liver Neoplasm	1
Fibrolamellar Carcinoma	1
Pancreatic Adenosquamous Carcinoma	1
Stage I Pancreatic Cancer AJCC v8	1
Consolidation	1
Advanced Gastroesophageal Junction Adenocarcinoma	1
Clinical Stage III Esophageal Adenocarcinoma AJCC v8	1
Ampulla of Vater Carcinoma	1
Appendix Carcinoma	1
Carcinoma of Unknown Primary With Gastrointestinal Profile	1
Borderline Ovarian Mucinous Tumor	1
Ovarian Mucinous Cystadenocarcinoma	1
Recurrent Fallopian Tube Carcinoma	1
Recurrent Ovarian Carcinoma	1
Stage II Rectal Cancer AJCC v8	1
Stage III Rectal Cancer AJCC v8	1
Locally Advanced Rectal Adenocarcinoma	1
Relapsed/Refractory Diffuse Large B Cell Lymphoma	1
Advanced Biliary Tract Carcinoma	1
Advanced Gallbladder Carcinoma	1
Advanced Intrahepatic Cholangiocarcinoma	1
Recurrent Biliary Tract Carcinoma	1
Stage II Colorectal Cancer AJCC v8	1
Stage III Colorectal Cancer AJCC v8	1
Stage IV Colorectal Cancer AJCC v7	1
Advanced Malignant Solid Neoplasm	1
Anatomic Stage III Breast Cancer AJCC v8	1
Anatomic Stage IV Breast Cancer AJCC v8	1
Locally Advanced Malignant Solid Neoplasm	1
Advanced Esophageal Squamous Cell Carcinoma	1
Metastatic Esophageal Squamous Cell Carcinoma	1
Pan-tumor	1
Unresectable Colorectal Cancer	1
Stomach Neoplasm	1

By country register

Register	Trials	Recruiting
Clinical trials in China	228	136
Clinical trials in USA	65	40
Clinical trials in Japan	52	29
Clinical trials in France	50	28
Clinical trials in Spain	44	25
Clinical trials in Italy	43	28
Clinical trials in Canada	41	22
Clinical trials in South Korea	40	27
Clinical trials in Germany	39	20
Clinical trials in Australia	31	19
Clinical trials in Mexico	30	12
Clinical trials in UK	29	18
Clinical trials in Netherlands	29	15
Clinical trials in Taiwan	29	15
Clinical trials in Brazil	25	17
Clinical trials in Belgium	24	12
Clinical trials in Israel	24	12
Clinical trials in Poland	22	14
Clinical trials in Turkey	19	13
Clinical trials in Czechia	13	7
Clinical trials in Switzerland	10	6
Clinical trials in Norway	10	4
Clinical trials in Portugal	9	6
Clinical trials in Austria	9	7
Clinical trials in Sweden	9	5
Clinical trials in Ireland	8	3
Clinical trials in India	8	5
Clinical trials in Denmark	8	4
Clinical trials in Singapore	6	3
Clinical trials in Egypt	5	4
EU register (CTIS)	16	—

A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.

Related compounds

Questions about Oxaliplatin trials

How many clinical trials are testing Oxaliplatin?

330 current trials in our China, USA, Japan, France, Spain, Italy, Canada, South Korea, Germany, Australia, Mexico, UK, Netherlands, Taiwan, Brazil, Belgium, Israel, Poland, Turkey, Czechia, Switzerland, Norway, Portugal, Austria, Sweden, Ireland, India, Denmark, Singapore and Egypt registers name Oxaliplatin (also registered as L01XA03) as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.

Are Oxaliplatin trials recruiting patients?

Yes. 189 of the 330 trials are recruiting: 136 with sites in China, 40 with sites in USA, 29 with sites in Japan, 28 with sites in France, 25 with sites in Spain, 28 with sites in Italy, 22 with sites in Canada, 27 with sites in South Korea, 20 with sites in Germany, 19 with sites in Australia, 12 with sites in Mexico, 18 with sites in UK, 15 with sites in Netherlands, 15 with sites in Taiwan, 17 with sites in Brazil, 12 with sites in Belgium, 12 with sites in Israel, 14 with sites in Poland, 13 with sites in Turkey, 7 with sites in Czechia, 6 with sites in Switzerland, 4 with sites in Norway, 6 with sites in Portugal, 7 with sites in Austria, 5 with sites in Sweden, 3 with sites in Ireland, 5 with sites in India, 4 with sites in Denmark, 3 with sites in Singapore and 4 with sites in Egypt. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Oxaliplatin clinical trials?

Fudan University (19), Sun Yat-sen University (13), Astellas Pharma Global Development, Inc (10) and Merck Sharp & Dohme LLC (7), among 164 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Are there Oxaliplatin clinical trials in Ireland?

Yes. 8 trials in our Ireland register (ClinicalTrials.gov), and 1 trial in the EU register (CTIS) list a site in Ireland. Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Is Oxaliplatin licensed in Ireland?

Yes. The HPRA medicines list includes 2 single-substance products containing Oxaliplatin, for example Oxaliplatin 5 mg/ml Concentrate for Solution for Infusion (Accord Healthcare Ireland Ltd.). A licence does not mean a product is currently marketed or reimbursed; see each product's record.

Is there a Oxaliplatin shortage?

The registers we track list 1 entry for Oxaliplatin: US FDA: resolved. Shortages are product- and country-specific; check with a pharmacist.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Oxaliplatin works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Oxaliplatin works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Oxaliplatin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.